Publication:
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.

Simple item page
dc.contributor.authorHizal, Mutlu
dc.contributor.authorBilgin, Burak
dc.contributor.authorPaksoy, Nail
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorSezer, Ahmet
dc.contributor.authorGürbüz, Mustafa
dc.contributor.authorAk, Naziye
dc.contributor.authorYücel, Şebnem
dc.contributor.authorAyhan, Murat
dc.contributor.authorErol, Cihan
dc.contributor.authorDemirkıran, Aykut
dc.contributor.authorMandel, Nil Molinas
dc.contributor.authorShbair, Abdallah
dc.contributor.authorGökmen, İvo
dc.contributor.authorBaşoğlu, Tuğba
dc.contributor.authorPaydaş, Semra
dc.contributor.authorDemiray, Atike Gökçen
dc.contributor.authorİriağaç, Yakup
dc.contributor.authorŞakalar, Teoman
dc.contributor.authorZeynelgil, Esra
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorBahçeci, Aykut
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorCaner, Burcu
dc.contributor.authorCan, Alper
dc.contributor.authorGülmez, Ahmet
dc.contributor.authorKarakaş, Yusuf
dc.contributor.authorYalçın, Bülent
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.authorBilici, Ahmet
dc.contributor.authorAydıner, Adnan
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.date.accessioned2023-05-16T15:24:00Z
dc.date.available2023-05-16T15:24:00Z
dc.date.issued2022-05-31T21:00:00Z
dc.description.abstractOsimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation.
dc.description.abstractThis retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety.
dc.description.abstractOf 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients.
dc.description.abstractOsimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile.
dc.identifier.pubmed34331582
dc.identifier.urihttps://hdl.handle.net/20.500.12645/37960
dc.language.isoen
dc.subjectEGFR
dc.subjectNon-small cell lung cancer
dc.subjectOsimertinib
dc.subjectSecond line
dc.subjectT790M
dc.titleThe real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
dspace.entity.typePublication
Files
Collections
Pubmed Ek Yayınlar